Zelasudil (RXC007)
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Key Facts
About Redx Pharma
Redx Pharma is a focused, AIM-listed biotech with a mission to translate innovative science into novel treatments for fibrosis and cancer. The company has achieved key milestones, including Fast Track designation for its lead GI-restricted ROCK inhibitor (RXC008) and reporting Phase 2a data for its systemic ROCK2 inhibitor, zelasudil (RXC007). Its strategy centers on a proprietary drug discovery platform, a balanced pipeline of proprietary and partnered assets, and a clear path to value inflection through clinical data readouts and strategic partnerships.
View full company profileAbout Redx Pharma
Redx Pharma is a focused, AIM-listed biotech with a mission to translate innovative science into novel treatments for fibrosis and cancer. The company has achieved key milestones, including Fast Track designation for its lead GI-restricted ROCK inhibitor (RXC008) and reporting Phase 2a data for its systemic ROCK2 inhibitor, zelasudil (RXC007). Its strategy centers on a proprietary drug discovery platform, a balanced pipeline of proprietary and partnered assets, and a clear path to value inflection through clinical data readouts and strategic partnerships.
View full company profile